Discovery of a peripheral 5HT2A antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitis

Discovery of a peripheral 5HT2A antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitis

Abstract Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is currently the leading cause of chronic liver disease worldwide. Metabolic Dysfunction-Associated Steatohepatitis (MASH), an advanced form of MASLD, can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Ba...

Full description

Bibliographic Details
Main Authors: Haushabhau S. Pagire, Suvarna H. Pagire, Byung-kwan Jeong, Won-Il Choi, Chang Joo Oh, Chae Won Lim, Minhee Kim, Jihyeon Yoon, Seong Soon Kim, Myung Ae Bae, Jae-Han Jeon, Sungmin Song, Hee Jong Lee, Eun Young Lee, Peter C. Goughnour, Dooseop Kim, In-Kyu Lee, Rohit Loomba, Hail Kim, Jin Hee Ahn
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-44874-3

Internet

https://doi.org/10.1038/s41467-024-44874-3

Similar Items